NCT06860529 is a Phase 2 clinical trial of Serplulimab in HR+/HER2- Breast Cancer, sponsored by Henan Cancer Hospital.

Who is sponsoring NCT06860529?

NCT06860529 is sponsored by Henan Cancer Hospital.

What drugs are being tested in NCT06860529?

Interventions in NCT06860529: Serplulimab, Epirubicin, Albumin Paclitaxel.

What condition does NCT06860529 study?

NCT06860529 studies HR+/HER2- Breast Cancer.

Is NCT06860529 still recruiting?

NCT06860529 is currently recruiting now. Last updated 23 June 2025.

Last reviewed 2025-06-23 · How we verify

NCT06860529

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Recruiting now Phase 2 Last updated 23 June 2025

What this trial tests

Phase 2 trial testing Serplulimab in HR+/HER2- Breast Cancer in 357 participants. Currently enrolling.

Timeline

15 April 2025

Primary endpoint
31 March 2028

31 March 2030

Quick facts

Lead sponsor	Henan Cancer Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	357
Start date	15 April 2025
Primary completion	31 March 2028
Estimated completion	31 March 2030
Sites	1 location across China

Drugs / interventions tested

Serplulimab — full drug profile →
Epirubicin (EPIRUBICIN) — full drug profile →
Albumin Paclitaxel — full drug profile →

Conditions studied

HR+/HER2- Breast Cancer — all drugs for HR+/HER2- Breast Cancer →

Sponsor

Henan Cancer Hospital

Who can join

18 and older, any sex, with HR+/HER2- Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The neoadjuvant treatment options commonly used for HR+/HER2- breast cancer are mainly anthracycline sequential or combined with paclitaxel chemotherapy regimens. Several clinical studies have confirmed that albumin paclitaxel is more effective than solvent-based paclitaxel, and therefore, albumin paclitaxel in combination with epirubicin has also become a commonly used chemotherapy regimen in clinical practice. The aim of this study was to explore the efficacy and safety of the Serplulimab combined with nab-paclitaxel and epirubicin in the neoadjuvant treatment of HR+/HER2- breast cancer

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Serplulimab

Trials testing the same drug.

NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07446465 — FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectab · Phase 4 · not yet recruiting
NCT07403435 — Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC · Phase 2 · not yet recruiting
NCT07381400 — Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Stu · Phase 2 · not yet recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting

Other recruiting trials for HR+/HER2- Breast Cancer

Currently open trials in the same condition.

NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
NCT06967103 — QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer · Phase 2 · recruiting
NCT06874933 — Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03) · Phase 2 · recruiting
NCT06977893 — Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Paralle · Phase 3 · recruiting
NCT07130643 — Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Brea · Phase 2 · active not recruiting

Other Henan Cancer Hospital trials

Trials by the same sponsor.

NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06860529 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
Last refreshed: 23 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06860529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing